Stem Sel business is based on the prototype development,
engineering, production, and commercialization of an instrumentation
(and related consumables) to select and sort human stem cells from
adult, "discarded" tissues (from cord blood or placental sources to
lipoaspirate or milkteeth) for applications in regenerative medicine.
Stem Sel has recently won the
2012 edition of StartCup 2013, the Emilia-Romagna business plan
competition involving the Spinner Program and all the Universities of
the Region. Stem Sel finally resulted to be winner among 52 projects
selected and advised by a board of business experts and investors.
...is still a prototype,
in-code named "Celector". The "celected" stem cells can be cultured and
directly used or committed to differentiated cells for applications in
cell therapy. The competitive advantage of "Celector" lies in its
ability to sort and select stem cells without any cell manipulation.
This is key factor to (1) pass regulatory restrictions, and (2)
select/sort stem cells for which there are not, as yet, efficient
technologies on the market. Indeed, the main competitor technologies
such as the flow-assisted cell sorting (FACS) and the magnetic-assisted
cell sorting (MACS®, Miltenyi Corp.) manipulate stem cell using
immunomarkers. Immunomarkers moreover are often not available to
efficiently select/sort multipotent stem cells such as MSCs. Compared
to the competitor technologies on the market, "Celector" also presents
the following key advantages: lower instrumental investment, lower
operation and maintenance costs, disposable cell fractionation device,
total preservation of cell viability, reduced operation times.
market and customers
The market for technology and tools for stem cell therapies
can be estimated to be in 2 years (2013-2014) as high as 400 M$ for US
and 1000 M$ in the world, and in 4 years (2016) as high as 800 M$ for
US and 2500 M$ in the world. Target clients of the "Celector" are stem
cell factories producing stem cell products for cell therapy, (cord
blood) stem cell banks for autologous transplantation applications, and
laboratories of stem cell manipulation for clinical applications. The
potential clients who might have the best goodwill to purchase the
"Celector" should be private cell factories developing cell therapies
based particularly on mesenchymal stem cells (MSCs), which are most
promising stem cells for tissue engineering. About 400 cell factories
in the world are currently sponsoring MSC-based clinical trials.
(President/CEO), full professor in Analytical Chemistry Andrea Zattoni
(CFO), researcher in Analytical Chemistry Barbara Roda
(CTO and Project Manager of “Celector”), researcher in Analytical
Martina Di Venere
(Product Manager of “Celector”), Biomedical Engineer Kristel Martinelli
(Quality Engineer di “Celector”), PhD student in Bioanalytical Chemistry Martina Rossi
(Solution Engineer di “Celector”), PhD student in Biotechnology Pietro Matiazzi,
Electronic Engineer of “Celector” Niccolò Dionisi,
Programmer of “Celector"
on business planning
The business plan involves the following phases, and it aims
the following goals:
R&D and technology-transfer development of the
Engineering of the relevant instrumentation at a
Small-scale commercialization (start-up production phase).
The proprietary technology is currently implemented in a
"Celector" lab-prototype. Activities for phase (1)
include development of the prototype, development of the stem cell
sorting protocols, and new applications of the implemented technology.
will be reached by a mix of make-or-buy actions. Phase (4)
will target clients among companies, hospitals and research
institutions running trials and applications on MSCs. The "Celector"
will be promoted by contacting the potential clients through
publications, expositions, symposia, and mainly by "hands-on"
demonstrations. With its own human resources Stem Sel will be able to
manage distribution and installation of "Celector" in Italy. To cover
the European market Stem Sel will reach an agreement with a distributor
with which byFlow is currently cooperating. To approach the North
American market, Stem Sel is currently working with two North American
consultants who will analyze the regional market and find out
technological partners, pilot clients, and possible distributors in
Stem Sel seeks investments for (1)
a 400.000€ "seed" round to cover the development and engineering of the
prototype to the ready-to-market phase, and for (2)
an additional venture capital round of ca. 1.0 million € to make Stem
Sel reach the start-up commercialization step. The Stem Sel start-up
phase will reach manufacturing of a limited number of "Celector"
package units. Stem Sel may prudentially estimate that during such a
start-up phase it will be able to reach a sale volume of at least 20
units the first year, and of at least 30 units the second year.
Dr.ssa Barbara Roda
Prof. Pierluigi Reschiglian
byFlow s.r.l. – solutions
in analytics for nano/biotechnology • Via Caduti
della Via Fani, 11/B - 40127 Bologna, Italy
P.IVA (VAT code) 03032331203 • Capitale sociale i.v.
(paid-up capital stock) 10.000€
Iscritta al Registro Imprese di Bologna (registered with the registrar
of companies, Bologna): n. 03032331203